

# Recurrent or Metastatic Head and Neck Cancer Pipeline Analysis 2024: Clinical Trials, FDA, EMA, PMDA Approvals

## *Recurrent or Metastatic Head and Neck Cancer Pipeline*

DELHI, DELHI, INDIA, July 9, 2024 /EINPresswire.com/ -- DelveInsight's, "Recurrent or Metastatic Head and Neck cancer Pipeline Insight 2024" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Recurrent or Metastatic Head and Neck cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Key Takeaways from the Recurrent or Metastatic Head and Neck cancer Pipeline Report

- DelveInsight's Recurrent or Metastatic Head and Neck cancer pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Recurrent or Metastatic Head and Neck cancer treatment.
- The leading Recurrent or Metastatic Head and Neck cancer Companies such as Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie, and others.
- Promising Recurrent or Metastatic Head and Neck Cancer Therapies such as docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU), Pemetrexed, Cetuximab, Carboplatin, and others.
- June 2024:- AVEO Pharmaceuticals Inc.- The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer.
- May 2024:- Alentis Therapeutics Inc- A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. The purpose of this study is to evaluate the safety profile of ALE.C04 monotherapy and in combination with pembrolizumab, to characterize pharmacokinetics profile of ALE.C04, recommended Phase II dose (RP2D) for ALE.

Explore our comprehensive Recurrent or Metastatic Head and Neck Cancer Pipeline Report to stay informed about the latest advancements. Download copy now @ [Recurrent or Metastatic Head and Neck Cancer Pipeline Outlook](#)

## Recurrent or Metastatic Head and Neck Cancer Overview

Traditionally patients with recurrence of head and neck cancer (HNC) are considered to have poor prognosis. As a result the majority of these patients are usually treated with palliative intent or receive best supportive care. Head and neck cancers are the sixth most common cancer worldwide, and arise from the upper aerodigestive mucosa, salivary glands, and skin. Despite differences in histology and biology across cancer types, most treatment protocols are extrapolated from head and neck squamous cell carcinoma (HNSCC the most common histology). Recurrent and metastatic disease is usually incurable. There are significant gaps in knowledge. Unlike other cancer types, there are no predictive biomarkers, and no new targeted therapies have been approved for HNSCC other than cetuximab in 2006.

## Recurrent or Metastatic Head and Neck cancer Emerging Drugs

- Xevinapant: Merck

Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care. Merck gains exclusive global development and commercialization rights; Debiopharm to receive € 188 million upfront and up to € 710 million in regulatory and commercial milestones, as well as royalty payments

- SI B001: Sichuan Baili Pharmaceutical

SI B001 is a bispecific antibody designed with the proprietary platform technology developed by Baili and SystImmune. It can bind to EGFR and HER3, and simultaneously inhibits the ligand induced EGFR×EGFR homodimers, the formation of EGFR×HER3 heterodimers and the activation of its downstream signal pathway. SI-B001 can also induce endocytosis of EGFR and HER3, and down-regulate the levels of EGFR and HER3 tumor cells. In preclinical studies, SI-B001 has demonstrated superior tumor killing activities. SI-B001 Phase I trials have shown good safety and preliminary efficacy.

Dive into our Recurrent or Metastatic Head and Neck Cancer Pipeline Report to uncover promising therapies and breakthroughs. Gain insights that could shape the future of oncology @ [Recurrent or Metastatic Head and Neck Cancer Treatment Landscape](#)

## Recurrent or Metastatic Head and Neck Cancer Therapeutics Assessment

There are approx. 40+ key companies which are developing the therapies Recurrent or Metastatic Head and Neck cancer. The companies which have their Recurrent or Metastatic Head and Neck cancer drug candidates in the most advanced stage, i.e phase III include Eisai Co

DelveInsight's Recurrent or Metastatic Head and Neck Cancer pipeline report covers around 40+ products under different phases of clinical development like

- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Download the Recurrent or Metastatic Head and Neck Cancer Pipeline Report to discover partnership opportunities and collaborate in driving impactful solutions forward @ [Recurrent or Metastatic Head and Neck Cancer Clinical Trials Assessment](#)

Recurrent or Metastatic Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

- Oral
- Intravenous
- Subcutaneous

Recurrent or Metastatic Head and Neck Cancer Products have been categorized under various Molecule types such as

- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy

Dive into our detailed Recurrent or Metastatic Head and Neck Cancer Pipeline Report to discover ground breaking advancements shaping the future of cancer treatment @ Recurrent or Metastatic Head and Neck Cancer Products, Companies, and Unmet Needs-

[https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=ypr](https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr)

Scope of the Recurrent or Metastatic Head and Neck Cancer Pipeline Report

- Coverage- Global
- Recurrent or Metastatic Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Recurrent or Metastatic Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Recurrent or Metastatic Head and Neck Cancer Companies- Eisai Co Ltd, Sinocelltech, Merck, Nanobiotix, Sichuan Baili Pharmaceutical, Adlai Nortye Biopharma, BioNTech, PDS Biotechnology, Shanghai Miracogen, Incyte Corporation, Checkmate Pharmaceuticals, NATCO Pharma, Agenus, Jiangsu Hengrui Medicine, Cue Biopharma, AbbVie, and others.
- Recurrent or Metastatic Head and Neck Cancer Therapies- docetaxel (XRP6976), cisplatin, 5-fluorouracil (5-FU), Pemetrexed, Cetuximab, Carboplatin, and others.

Gain valuable insights into emerging therapies and innovations with our Recurrent or Metastatic Head and Neck Cancer Pipeline Report @ Recurrent or Metastatic Head and Neck Cancer Market

Drivers and Barriers, Future Perspectives and Analyst Views-

[https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=ypr](https://www.delveinsight.com/sample-request/recurrent-or-metastatic-head-and-neck-cancer-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=ypr)

## Table of Content

1. Introduction
2. Executive Summary
3. Recurrent or Metastatic Head and Neck cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Recurrent or Metastatic Head and Neck cancer– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Lenvatinib: Eisai Co
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. SI B001: Sichuan Baili Pharmaceutical
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. Revdofilimab: AbbVie
15. Drug profiles in the detailed report.....
16. Early Stage Products (Preclinical)
17. Drug name: Company name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Recurrent or Metastatic Head and Neck cancer Key Companies
21. Recurrent or Metastatic Head and Neck cancer Key Products
22. Recurrent or Metastatic Head and Neck cancer- Unmet Needs
23. Recurrent or Metastatic Head and Neck cancer- Market Drivers and Barriers
24. Recurrent or Metastatic Head and Neck cancer- Future Perspectives and Conclusion
25. Recurrent or Metastatic Head and Neck cancer Analyst Views
26. Recurrent or Metastatic Head and Neck cancer Key Companies
27. Appendix

## About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Yash Bhardwaj  
DelveInsight

+91 9650213330

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/726280043>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.